Potential Side Effects of GLP-1 Agonists and How to Mitigate Them

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 agonists may cause nausea, vomiting, and diarrhea; gradual dose escalation and dietary changes can help minimize these side effects for better tolerance.

# Potential Side Effects of GLP-1 Agonists and How to Mitigate Them

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications widely used to treat type 2 diabetes and obesity. These injectable or oral drugs mimic the effects of the naturally occurring hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. While highly effective for glycemic control and weight management, GLP-1 agonists may cause certain side effects that can affect patient adherence and outcomes.

In this article, we will explore the common and less common side effects of GLP-1 receptor agonists, practical strategies to mitigate them, and dosing considerations. As always, patients should consult their healthcare provider before starting or stopping any medication.

---

Common Side Effects of GLP-1 Agonists

1. Gastrointestinal Symptoms

The most frequently reported side effects of GLP-1 receptor agonists involve the gastrointestinal (GI) tract, including:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain or discomfort

    • These symptoms are primarily related to the drugs’ mechanism of slowing gastric emptying and increasing satiety.

    2. Hypoglycemia

    When combined with other glucose-lowering agents, especially insulin or sulfonylureas, GLP-1 agonists may increase the risk of hypoglycemia. However, when used alone, hypoglycemia risk is generally low due to their glucose-dependent mode of action.

    3. Injection Site Reactions

    For injectable formulations, some patients experience redness, itching, or discomfort at the injection site.

    ---

    Less Common But Notable Side Effects

    1. Pancreatitis

    Cases of pancreatitis have been reported, though causality remains controversial. Patients should be informed of symptoms such as severe abdominal pain and seek immediate medical attention if they occur.

    2. Gallbladder Disease

    An increased risk of gallstones and cholecystitis (gallbladder inflammation) has been observed in some studies.

    3. Kidney Injury

    GLP-1 agonists can cause dehydration from vomiting or diarrhea, potentially leading to acute kidney injury, especially in patients with pre-existing kidney disease.

    4. Thyroid C-cell Tumors

    Animal studies suggested a risk of thyroid C-cell tumors, but this has not been confirmed in humans. However, these medications are typically avoided in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

    ---

    Mitigating Side Effects: Practical Protocols

    Start Low, Go Slow

  • Initiate therapy at the lowest recommended dose to minimize GI side effects.
  • Gradually titrate the dose every 1-2 weeks based on tolerance and glycemic targets.

    • Dietary Recommendations

  • Small, frequent meals: Help reduce nausea and improve digestion.
  • Avoid fatty or spicy foods: These can exacerbate GI discomfort.
  • Stay hydrated: Drinking adequate fluids reduces dehydration risk.

    • Monitor Blood Glucose Closely

  • Adjust concurrent insulin or sulfonylurea doses to lower the risk of hypoglycemia.
  • Use glucose monitoring to tailor therapy.

    • Injection Technique

  • Rotate injection sites to prevent local reactions.
  • Use proper injection technique and sterile equipment.

    • Patient Education

  • Inform about potential side effects and management strategies.
  • Advise to promptly report severe abdominal pain or persistent GI symptoms.

    • Monitoring for Rare Adverse Events

  • Conduct regular kidney function tests, especially if patients develop vomiting or diarrhea.
  • Evaluate thyroid function periodically if clinically indicated.

    • ---

    Dosing Information of Common GLP-1 Agonists

    | Medication | Starting Dose | Maintenance Dose | Notes |

    |---------------------|----------------------------|------------------------|------------------------------------------|

    | Exenatide (Byetta) | 5 mcg twice daily | 10 mcg twice daily | Administer within 60 min before meals |

    | Liraglutide (Victoza) | 0.6 mg daily | 1.2-1.8 mg daily | Dose up-titrated after 1 week |

    | Dulaglutide (Trulicity) | 0.75 mg once weekly | 1.5 mg once weekly | Single-use pen injection |

    | Semaglutide (Ozempic) | 0.25 mg once weekly | 0.5-1 mg once weekly | Start low to improve tolerability |

    | Oral Semaglutide (Rybelsus) | 3 mg once daily | 7-14 mg once daily | Take with limited water; wait 30 min before food |

    Dosing should always be individualized by a healthcare provider.

    ---

    Conclusion

    GLP-1 receptor agonists are effective and increasingly popular for managing type 2 diabetes and obesity, offering benefits beyond glucose control, including weight loss and cardiovascular protection. However, gastrointestinal side effects remain the most common hurdle, and awareness of less common but serious risks is essential.

    To maximize benefits and minimize risks:

  • Start at lower doses with gradual titration.
  • Follow dietary and hydration guidelines.
  • Monitor blood glucose and renal function.
  • Educate patients thoroughly on what to expect and when to seek care.

    • Patients should always consult their healthcare provider before starting or adjusting GLP-1 agonist therapy to ensure safe and effective use tailored to their medical condition.

    ---

    References

  • Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21.
  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
  • American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S98-S110.
  • Davies MJ, Aramis A, Rutten GE, et al. Safety and tolerability of GLP-1 receptor agonists in type 2 diabetes: A systematic review. Diabetes Obes Metab. 2018;20(9):1983-1995.

    • ---

    This article is for informational purposes only and is not a substitute for professional medical advice.